vs
Side-by-side financial comparison of Cytek Biosciences, Inc. (CTKB) and Vanda Pharmaceuticals Inc. (VNDA). Click either name above to swap in a different company.
Cytek Biosciences, Inc. is the larger business by last-quarter revenue ($62.1M vs $57.2M, roughly 1.1× Vanda Pharmaceuticals Inc.). Cytek Biosciences, Inc. runs the higher net margin — -70.9% vs -246.8%, a 175.8% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 7.6%). Cytek Biosciences, Inc. produced more free cash flow last quarter ($-1.8M vs $-29.5M). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 9.8%).
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
CTKB vs VNDA — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $62.1M | $57.2M |
| Net Profit | $-44.1M | $-141.2M |
| Gross Margin | 52.9% | — |
| Operating Margin | -9.0% | -70.5% |
| Net Margin | -70.9% | -246.8% |
| Revenue YoY | 8.1% | 7.6% |
| Net Profit YoY | -557.1% | -2774.3% |
| EPS (diluted) | — | $-2.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $62.1M | $57.2M | ||
| Q3 25 | $52.3M | $56.3M | ||
| Q2 25 | $45.6M | $52.6M | ||
| Q1 25 | $41.5M | $50.0M | ||
| Q4 24 | $57.5M | $53.2M | ||
| Q3 24 | $51.5M | $47.7M | ||
| Q2 24 | $46.6M | $50.5M | ||
| Q1 24 | $44.9M | $47.5M |
| Q4 25 | $-44.1M | $-141.2M | ||
| Q3 25 | $-5.5M | $-22.6M | ||
| Q2 25 | $-5.6M | $-27.2M | ||
| Q1 25 | $-11.4M | $-29.5M | ||
| Q4 24 | $9.6M | $-4.9M | ||
| Q3 24 | $941.0K | $-5.3M | ||
| Q2 24 | $-10.4M | $-4.5M | ||
| Q1 24 | $-6.2M | $-4.1M |
| Q4 25 | 52.9% | — | ||
| Q3 25 | 52.7% | — | ||
| Q2 25 | 52.3% | — | ||
| Q1 25 | 48.6% | — | ||
| Q4 24 | 58.5% | — | ||
| Q3 24 | 56.3% | — | ||
| Q2 24 | 54.6% | — | ||
| Q1 24 | 51.3% | — |
| Q4 25 | -9.0% | -70.5% | ||
| Q3 25 | -17.6% | -55.6% | ||
| Q2 25 | -23.3% | -73.2% | ||
| Q1 25 | -36.1% | -82.0% | ||
| Q4 24 | 5.2% | -19.3% | ||
| Q3 24 | -8.2% | -23.1% | ||
| Q2 24 | -18.3% | -20.1% | ||
| Q1 24 | -23.9% | -19.5% |
| Q4 25 | -70.9% | -246.8% | ||
| Q3 25 | -10.5% | -40.1% | ||
| Q2 25 | -12.2% | -51.7% | ||
| Q1 25 | -27.5% | -58.9% | ||
| Q4 24 | 16.8% | -9.2% | ||
| Q3 24 | 1.8% | -11.2% | ||
| Q2 24 | -22.4% | -9.0% | ||
| Q1 24 | -13.8% | -8.7% |
| Q4 25 | — | $-2.40 | ||
| Q3 25 | — | $-0.38 | ||
| Q2 25 | — | $-0.46 | ||
| Q1 25 | — | $-0.50 | ||
| Q4 24 | — | $-0.09 | ||
| Q3 24 | — | $-0.09 | ||
| Q2 24 | — | $-0.08 | ||
| Q1 24 | — | $-0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $90.9M | $84.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $341.7M | $327.2M |
| Total Assets | $461.5M | $488.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $90.9M | $84.9M | ||
| Q3 25 | $93.3M | $70.0M | ||
| Q2 25 | $75.5M | $81.0M | ||
| Q1 25 | $95.3M | $111.8M | ||
| Q4 24 | $98.7M | $102.3M | ||
| Q3 24 | $162.3M | $100.5M | ||
| Q2 24 | $177.9M | $103.0M | ||
| Q1 24 | $168.8M | $125.2M |
| Q4 25 | $341.7M | $327.2M | ||
| Q3 25 | $378.6M | $466.0M | ||
| Q2 25 | $377.6M | $486.3M | ||
| Q1 25 | $379.6M | $511.4M | ||
| Q4 24 | $395.7M | $538.5M | ||
| Q3 24 | $385.5M | $541.2M | ||
| Q2 24 | $389.1M | $542.5M | ||
| Q1 24 | $392.6M | $544.0M |
| Q4 25 | $461.5M | $488.9M | ||
| Q3 25 | $494.9M | $601.1M | ||
| Q2 25 | $493.3M | $624.7M | ||
| Q1 25 | $482.6M | $631.9M | ||
| Q4 24 | $499.5M | $656.2M | ||
| Q3 24 | $491.2M | $645.1M | ||
| Q2 24 | $483.7M | $651.4M | ||
| Q1 24 | $492.1M | $652.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-771.0K | $-29.4M |
| Free Cash FlowOCF − Capex | $-1.8M | $-29.5M |
| FCF MarginFCF / Revenue | -2.9% | -51.6% |
| Capex IntensityCapex / Revenue | 1.6% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-8.8M | $-110.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-771.0K | $-29.4M | ||
| Q3 25 | $-3.9M | $-31.6M | ||
| Q2 25 | $108.0K | $-15.3M | ||
| Q1 25 | $-125.0K | $-33.1M | ||
| Q4 24 | $2.0M | $-1.8M | ||
| Q3 24 | $13.2M | $-14.6M | ||
| Q2 24 | $6.2M | $-6.9M | ||
| Q1 24 | $4.0M | $7.6M |
| Q4 25 | $-1.8M | $-29.5M | ||
| Q3 25 | $-4.6M | $-31.8M | ||
| Q2 25 | $-1.5M | $-15.6M | ||
| Q1 25 | $-974.0K | $-33.6M | ||
| Q4 24 | $1.1M | $-2.0M | ||
| Q3 24 | $12.2M | $-14.7M | ||
| Q2 24 | $5.2M | $-7.0M | ||
| Q1 24 | $3.4M | $7.6M |
| Q4 25 | -2.9% | -51.6% | ||
| Q3 25 | -8.7% | -56.5% | ||
| Q2 25 | -3.2% | -29.6% | ||
| Q1 25 | -2.3% | -67.1% | ||
| Q4 24 | 1.9% | -3.8% | ||
| Q3 24 | 23.7% | -30.9% | ||
| Q2 24 | 11.0% | -13.9% | ||
| Q1 24 | 7.6% | 15.9% |
| Q4 25 | 1.6% | 0.2% | ||
| Q3 25 | 1.3% | 0.3% | ||
| Q2 25 | 3.5% | 0.6% | ||
| Q1 25 | 2.0% | 0.9% | ||
| Q4 24 | 1.6% | 0.4% | ||
| Q3 24 | 2.0% | 0.3% | ||
| Q2 24 | 2.3% | 0.2% | ||
| Q1 24 | 1.3% | 0.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 14.05× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
VNDA
| Fanapt | $33.2M | 58% |
| Hetlioz | $16.4M | 29% |
| PONVORY | $7.6M | 13% |
